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Abstract. Epilepsy often affects cognition. The aim of this review was to systematically 
examine evidence for the validity of cognitive screening tests currently being used in 
epilepsy. MEDLINE and EMBASE databases were searched from 1946/1947 until the 
12th of March 2019. Only studies that met the eligibility criteria and which reported at 
least some diagnostic accuracy data were included. Seven studies met the inclusion 
criteria, relating to five screening tools. The EpiTrack was the most commonly used 
tool, while the test most frequently used as a reference standard was the Digit Span. 
Diagnostic accuracy of cognitive screening tools in epilepsy remains limited and the 
risk of bias is generally high. EpiTrack is proposed as the appropriate screening tool to 
begin the assessment with, as it is specifically constructed for and validated on patients 
with epilepsy, provides specific cutoff points, and has satisfactory reliability. 
 











Epilepsy is defined as: "(1) at least two unprovoked (or reflex) seizures occurring > 24 h 
apart; (2) one unprovoked (or reflex) seizure and a probability of further seizures similar 
to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring 
over the next 10 years from the initial seizure; (3) diagnosis of an epilepsy syndrome 
(Fisher et al., 2014). It can be the result of several underlying causes (de Groot et al., 
2012; Hauser & Hesdorffer, 1990; Staley et al., 2011) and is among the 25 most 
common conditions leading patients to spend years living with a disability (Vos et al., 
2012). Epilepsy has a great impact in many domains of patients’ lives (Jones-Gotman et 
al., 2010) and affects cognition because of various reasons: the epileptiform activity, 
which is produced by the condition itself, underlying pathologies that cause the 
epilepsy, medication side effects, potential cumulative head injuries from unexpected 
collapse, and in some cases consequences of surgery (Gavrilovic et al., 2019; Kwan & 
Brodie, 2001; Meschede et al., 2018; Staley et al., 2011; Witt et al., 2018; Zhang et al., 
2018).  
More specifically, it has been found that epileptiform discharges predicted 
cognitive ability in general and memory function in sixty-nine patients with genetic 
generalised epilepsy (Loughman et al., 2016). Patients with temporal lobe epilepsy 
show impairments either in multiple cognitive domains, or specifically in attention and 
executive functions, frontal lobe functions, memory, or language (Allone et al., 2017; 
Noebels, 2011; Uslu et al., 2019). Furthermore, according to Lin et al. (2012), various 
types of anti-epileptic medication have negative effect on motor or cognitive speed, 
mood, and memory. Finally, research in children with epilepsy has detected impaired 
intelligence scores, executive functions, visual attention, and spatial ability (Cheng et 
al., 2017; Lin et al., 2012). Indeed, in the review of MacAllister and Schaffer (2007), 
impairments in global cognitive functioning, visual spatial function, visual and verbal 
memory, attention, executive functioning, and language abilities, were found in children 
with different epilepsy types, including generalized idiopathic epilepsies ̶ e.g., 
childhood and juvenile absence epilepsy ̶ or focal epilepsies such as temporal lobe 
epilepsy, frontal lobe epilepsy, the Lennox–Gastaut Syndrome, and West Syndrome.  
It is therefore pivotal to examine patients’ cognitive abilities in order to 
investigate possible cognitive changes as a result of epileptiform activity, medication 
prescribed, or surgical impact. However, administering a comprehensive 
neuropsychological battery on a frequent basis is not always feasible, as is time-
consuming and cost-intensive; a screening test that can be administered quickly and 
reliably to give an impression of cognitive change is therefore desirable in busy clinical 
settings (Wilson et al., 2015).  
There are several tools that have been used in the past to screen for impairment 
in persons with epilepsy, either in clinical practice or in research (Huang et al., 2005; 
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Natham et al., 2018; Witt et al., 2015). Among the tools used, were the Cognitive 
Ability Screening Instrument (CASI; Teng et al., 1996), the Mini-Mental State 
Examination (MMSE) (Folstein et al., 1975) and the Montreal Cognitive Assessment 
(MOCA; Nasreddine et al., 2005). Specifically, researchers sought to examine cognitive 
impairment in specific types of epilepsy (Phabphal & Kanjanasatien, 2011), to assess 
the consequences of surgery (Zhang et al., 2018), the impact of anti-epileptic 
medication on cognition (Liguori et al., 2018), to investigate the association of cognitive 
impairment with other factors (Palanisamy et al., 2016).  
However, none of these studies looked at diagnostic accuracy in terms of the 
ability of these screening tools to identify cognitive impairment in epilepsy based on a 
cutoff score. Additionally, no review has been carried out regarding the most 
appropriate/sensitive cognitive screening test that can be used specifically to screen this 
population. Research in this domain could help clinicians select the best tool to utilise in 
order to assess patients briefly, detect possible impairment and suggest whether a 
patient would benefit from a comprehensive neuropsychological assessment. The aim of 
this review was to systematically examine the existing literature regarding cognitive 
screening tests used in epilepsy patients, focusing on evidence on their validity. This 
will contribute to the discussion about the accuracy of standardized cognitive screening 






The target condition was epilepsy, as defined by the International League Against 
Epilepsy (Fisher et al., 2014), with the population of interest being people with epilepsy. 
The index tests were the cognitive screening tests used, whereas reference standards 




The studies to be included in this review had to fulfill the following eligibility criteria: 
a) Firstly, they were validation studies (meaning that the goal of the study was to 
investigate if the tool was able to distinguish between patients with and without 
cognitive impairment based on either diagnostic accuracy statistics, or statistical 
significance between groups; b) they were empirical studies presenting original results 
(i.e., the results should not constitute part of a review); c) the results were compared to 
another reference standard (as there are no specific cognitive tests that diagnose 
cognitive impairment in epilepsy, there were no limitations regarding the reference 
standards being used); d) the full article should be available (not just the abstracts or 
conference proceedings); e) the language in which the papers were published should be 
English. 





For this review, MEDLINE [Ovid MEDLINE(R) and Epub Ahead of Print, In-Process 
& Other Non-Indexed Citations, Daily and Versions(R) 1946 to date] and EMBASE 
(Embase 1947-Present, updated daily) were searched. The keywords and subject 
headings used are shown in Table 1. The search included only studies published in 
English and the dates were set as beginning from 1946 and 1947 respectively to the 12th 
of March 2019. 
 
Table 1. Keywords and MeSH terms of search strategy used in MEDLINE and 
EMBASE databases study selection 
 
Study selection 
             
After the appropriate terms were inserted in the database, the process of study selection 
started. First, all duplicates were removed. Next, all titles and abstracts were screened. 
After the studies considered to match the review question were identified from title 
and/or abstract, the full-text articles were read to determine which articles fully met the 
eligibility criteria and could be included in the review. 
The flow chart of this study is presented according to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) standards (Moher et al., 
2009) in Figure 1.  




Figure 1. Flow diagram describing search strategy and results 
 





Key study information was recorded in a data extraction form that included: sample 
size; place of examination (e.g., day care centre); tests given; reference standards used; 
time intervals. In a separate table, descriptive details of the studies were summarized, 
detailing the sample size and demographic characteristics as well as which of the 
diagnostic accuracy features (reliability, validity, sensitivity, specificity, positive 
predictive values (PPV), negative predictive values (NPV), cutoffs) were reported in 
each of the studies. 
 
Quality assessment  
 
To assess the quality of the studies, Version 2 of the Quality Assessment of Diagnostic 
Accuracy Studies (QUADAS-2) (Whiting et al., 2011) was used. This tool assesses four 
domains; specifically, it examines the participants, index test, reference standard and 
flow and timing of the studies. In each of the four domains, the rater had to assess two 
factors, namely, risk of bias and applicability of the study. This means that the rater 
decided, for example, if the selection of participants, the tools administered, etc., could 
potentially be considered as biased, and also if there were aspects of the study which 
may render it inappropriate to the review question. In order for the author to decide, 
there were signaling questions in each domain and after careful consideration the user 
marked the signaling questions on a scale with three choices (low/high/unclear). After 
the two signaling questions in the risk of bias section and the one signaling question in 
the applicability section were marked, the first author of the study gave a total mark for 




The findings of the studies were summarised in tables. Descriptions of the screening 
tools included in the review, such as details of the subtests they consisted of, the 
functions they assessed and the form of test administration (i.e., paper and pencil or 
computerised) were also provided. Meta-analysis was not possible due to heterogeneity 








A total of 634 records were initially identified. After duplicates were excluded, 467 
records were screened. Based on titles and abstracts, 391 records were excluded, leaving 
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76 for full text review. After careful reading of full texts seven studies met the 
eligibility criteria and were included in the review. The detailed process and reasons for 
exclusion of studies are presented in Figure 1. 
 
 
Description of studies 
 
 
The seven studies which were included in this review (Gao et al., 2014; Helmstaedter et 
al., 2010; Hoppe et al., 2009; Kadish et al., 2013; Kurzbuch et al., 2013; Lutz & 
Helmstaedter, 2005; Walterfang et al., 2011) were published in English between 2005 
and 2014.  
The sample sizes for healthy controls ranged in five studies from 83 to 277 
persons whereas two of the studies did not recruit healthy people; one study compared 
the epilepsy group against dementia and neurological disorders group and the other 
study compared patients’ data with healthy controls’ mean scores acquired from a 
previous validation study. As far as clinical samples are concerned, the number of 
participants ranged in the seven studies from 22 to 240, with age between 6 and 74 
years. In terms of education level, there were people with no specific qualification, as 
well as participants who had obtained various years of formal education. All studies 
included both males and females. Participants of two studies were children. In Table 2 
sample sizes and demographic characteristics are given in detail. 
Reporting on source of recruitment varied. With regards to healthy controls, four 
out of the five studies that included healthy participants did not state where those 
participants were recruited from. Only one of the five studies that recruited healthy 
controls reported on the source of the sample (students from three different 
representative schools in Germany). Clinical participants in the seven studies were 
recruited from epilepsy centers in hospitals or clinics.  
Finally, there was variation regarding the type of epilepsy participants suffered 
from. Participants suffered from absence epilepsy in one study; they were divided into 
epilepsy and psychogenic epilepsy subcategories in another study, but in the rest of the 















Table 2. Demographic characteristics of the studies’ samples 
 
 
Note: The abbreviations used: med. educ. = medium education, hig. educ. = higher education, NR = not 
reported. NA = this characteristic did not exist or was not calculated at all. 
*No changes have been made in the way of reporting the characteristics; all information is stated as it was 
presented in the original studies 




Cognitive screening tests 
 
 
In the seven studies that were included in this review, there were five screening tests 
validated: EpiTrack, EpiTrack Junior, Neuropsychiatry Unit Cognitive Assessment Tool 
(NUCOG), Neurocognitive Effects (NeuroCog FX) and the Computerized Cognitive 
Testing in Epilepsy (CCTE). In detail, one study examined the validity of the EpiTrack 
screening tool in adults with epilepsy, two studies used the EpiTrack Junior in children, 
one in children with unspecified epilepsy, and one study in children with absence 
epilepsy. Two studies examined the validity of the NUCOG in adults. In the other two 
papers, researchers sought to validate two computerised screening tests: the NeuroCog 
FX and the CCTE cognitive screening tools. Description of the tools is given in Table 3 
and the results found by each study are shown in Table 4. 
 As seen in Table 4, different types of validity were used by the seven studies. 
Overall, the three types of validity used by the researchers to compare the index tests 
with the reference standards were convergent, concurrent and discriminant validity, 
which may all be considered as forms of the broader category of construct validity 
(DeVon et al., 2007). More specifically, construct validity is defined as “the degree to 
which an instrument measures the construct it is intended to measure” (DeVon et al., 
2007, p. 156). Regarding the three types that were used by the studies included in this 
systematic review, concurrent validity was used to define the degree to which the scores 
on a test being used were correlated with another criterion at the same time point. 
Convergent validity was used when the goal was to check correlation between tools that 
measure the same construct, whereas discriminant validity is the ability of a tool to 
differentiate between different constructs. 
            Regarding the thresholds which are necessary so that the clinicians know when 
the patients are potentially in the impairment range, a cutoff point based on optimal 
sensitivity/specificity in the study sample was suggested for NeuroCog FX, whereas for 
the EpiTrack and EpiTrack Junior the suggested cutoffs were based on means, standard 
deviation of the raw scores and frequencies of scores. In the studies of EpiTrack junior 
in absence epilepsy and NUCOG the researchers used cutoffs set from previous 
validation studies. Additionally, in the studies of the NUCOG Chinese and CCTE, 
neither a new cutoff was suggested nor was it mentioned if the researchers used a 
threshold from previous studies and what it would be; sensitivity and specificity values, 
PPV and NPV were not reported either, though reliability (test -retest) and/or validity 
(concurrent) values were provided.  
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Table 3. Description of the cognitive screening tests 
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Table 4. Results of included studies 
 
Abbreviations: ? = not reported, con = convergent, conc = concurrent, disc = discriminant,  
CIT = test for cerebral inefficiency, TMT = trail making test, VLMT = Rey auditory verbal learning test, 
DCS = Diagnosticum für Cerebral schädigung – revidiert, ROCFT — Rey–Osterrieth Complex Figure 
Test. HAWIK-IV — German equivalent of WISC-IV. 
a = Pearson’s Coefficient, b = Cronbach’s α, c = Spearman’s, d = nonsignificant 
Note: In the cases that various values were presented (e.g., one for each subtest), values were presented in 
ranges (~). 
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            In summary, regarding the studies included in this review, there was variation in 
terms of the number of reference standards used (see the next section). One study 
(Helmstaedter et al., 2010) did not report validity rates. In three of the six remaining 
studies, the validity rates were relatively high (Gao et al., 2014; Kurzbuch et al., 2013; 
Lutz & Helmstaedter, 2005), but in these studies only a limited number of tests were 




The diagnostic criteria for epilepsy do not require cognitive impairment (Fisher et al., 
2014). That is, cognitive impairment is not inevitable in epilepsy. The purpose of using 
a cognitive screening tool in patients with epilepsy is to identify whether cognitive 
impairment ̶ resulting from epilepsy related factors ̶ is present. Thus, in relation to a 
reference standard, other tests or measures known to be sensitive to cognitive 
impairment are required. However, given that there are a very large number of cognitive 
tests, then it is perhaps to be expected that the reference standards used in validation 
studies of cognitive screening tools varies considerably. 
The most commonly used reference test was the Digit Span (Wechsler, 1997a) 
as an index of working memory function, which was used in four of the seven studies 
(Hoppe et al., 2009; Kadish et al., 2013; Lutz & Helmstaedter, 2005; Walterfang et al., 
2011). Moreover, three tests were common to three studies. These were the Trail 
Making Test, which measures scanning, speed of processing, visual search, mental 
flexibility but also executive functions (Reitan & Wolfson, 1985; Tombaugh, 2004) and 
which was used in the following studies: Hoppe et al. (2009), Kurzbuch et al. (2013) 
and Walterfang et al. (2011); a German version of the Rey Auditory Verbal Learning 
Test (Helmstaedter et al., 2001; Rey, 1958) -which examines verbal learning and 
memory-, used in the Hoppe et al. (2009), Kadish et al. (2013) and Kurzbuch et al. 
(2013) studies; finally, subtests assessing verbal learning and memory from Wechsler 
scales, (Wechsler, 1997a) were used in Kadish et al. (2013), Kurzbuch et al. (2013) and 
Walterfang et al. (2011) studies.  
In addition, verbal fluency was measured using the Regensburger 
Wortflüssigkeits-Test (RWT; Aschenbrenner et al., 2010) in Kadish et al. study (2013), 
whereas Walterfang et al. (2011) used the Delis–Kaplan Executive Function System 
(DKEFS; Delis et al., 2001) to assess the same function. The Diagnosticum for Cerebral 
Impairment (Weidlich et al., 2001) - which measures figural memory - was used in two 
studies, namely by Kurzbuch et al. (2013) and Hoppe et al. (2009). Τhe Maze Test 
(Chapuis et al., 1992), which measures anticipation and planning, was also used in two 
studies: in Lutz and Helmstaedter (2005) and Hoppe et al. (2009). The Block Design 
which examines visuoconstructional functions (Wechsler, 1997a) was used in the 
studies of Lutz and Helmstaedter (2005) and Walterfang et al. (2011). Also, Kadish et 
al. (2013) and Walterfang et al., (2011) used the Rey Osterreith Complex Figure Test 
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(ROCFT; Osterreith, 1944; Rey, 1941) to measure visuo-constructional abilities and 
non-verbal memory.  
Finally, there were subtests or screening tools that were utilized by one study 
only. In the validation of NeuroCog FX (Hoppe et al, 2009) the index test was 
compared with three tests: the Performance Test System which measures word fluency 
(Horn, 1983), the Dementia Test, measuring memory, verbal fluency, orientation and 
praxis (Kessler et al., 1988), and the Test for Cerebral Insufficiency (CIT; Lehrl, 1997). 
Also, in the validation of EpiTrack (Lutz & Helmstaedter, 2005) additional tests were 
used to examine the convergent validity, such as Mental Rotation, which examines 
spatial ̶ visualization abilities (Vandenberg & Kuse, 1978), Corsi block tapping, 
assessing non-verbal learning and memory (Corsi, 1972) and other, non-standardised 
tasks assessing attention and executive functions such as symbol counting, motor 
sequences and letter cancelation. Additionally, the Chinese version of NUCOG (Gao et 
al., 2014) was the only screen validated against a cognitive screening tool, specifically 
the Mini Mental State Examination which assesses orientation to time and place, 
registration and recall of three words, attention and calculation, language, and visual 
construction (Folstein et al., 1975). In the validation of the English NUCOG 
(Walterfang et al., 2011), several tasks from the Wechsler intelligence and memory 
scales (WAIS/WMS; Wechsler, 1997a; 1997b) were also used, specifically: Matrix 
Reasoning, Vocabulary, Information, Similarities, Visual Reproduction, and Logical 
Memory. The Boston Naming Test (Kaplan et al., 1976) examining word retrieval and 
the Wechsler Test of Adult Reading (Wechsler, 2001) for the assessment of premorbid 
IQ were used for estimating IQ. Finally, for the validation of EpiTrack Junior 
(Helmstaedter et al., 2010), the performances of the patients on the index test were 






The studies were assessed in terms of quality of diagnostic accuracy, risk of bias and 
applicability as rated by the QUADAS-2 tool (Whiting et al., 2011). Each of the four 
domains of QUADAS-2 tool was marked as having low, high or unclear risk of bias and 
concerns of applicability to this review with reference to specific signaling questions. 
Thus, regarding applicability concerns, all seven studies had low risk in all the three 
domains (patient selection, index test, and reference standard). Regarding risk of bias, 
six studies were characterised as low risk in the patient selection domain and one study 
as high risk. However, in the index test, reference standard and flow and timing 
domains, most of the studies were marked as having either high risk or as unclear. The 
detailed description of the studies in terms of QUADAS-2 assessment is given in Table 
5. 
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According to the conclusions of the authors of the studies reviewed, all five 
tools  ̶ NeuroCog FX, CCTE, EpiTrack, NUCOG, and EpiTrack Junior ̶  proved valid 
for use in epilepsy patients. More specifically, NeuroCog FX and CCTE were suggested 
for use in clinical and research settings; Hoppe et al. (2009) suggested that NeuroCog 
FX provides reliable and valid cognitive assessment, while Kurzbuch et al. (2013) 
supported that CCTE provides effective screening of memory and executive functions 
and discriminates different levels of impairment in relation to medication effects. Lutz 
and Helmstaedter (2005) suggested that EpiTrack provides prompt results, facilitating 
the diagnostic process. Additionally, Gao et al. (2014) reported that NUCOG was a 
reliable and sensitive tool, able to differentiate cognitive decline in certain seizure types. 
Finally, EpiTrack Junior was suggested by Helmstaedter et al. (2010) as a valid and 
reliable tool to assess executive functions in children with epilepsy and absence 
epilepsy. However, it is possible that the authors made those conclusions based only on 
reliability and validity measures of the studies. Perhaps, additional diagnostic accuracy 
values could be reported by the authors, for the quality of the studies to be improved. As 
shown in Table 4, only one of the seven studies provided Positive Predictive Values 
(PPVs) and Negative Predictive Values (NPVs) and only two studies in total provided 
sensitivity and specificity rates. Despite important information missing, the tools were 






The purpose of this review was to summarise the existing literature on cognitive 
screening tools in patients with epilepsy, to investigate the quality of the studies, and to 
identify priorities for future research.  
In total, seven studies were found, in which researchers examined the validity of 
screening tools in detecting cognitive impairment in epilepsy patients. The total number 
of screening tools used was even lower than the studies found, namely five  ̶ the 
EpiTrack and the EpiTrack Junior version for children, the NUCOG, the NeuroCog FX, 
and the CCTE ̶  which is a low number, compared to the number of validation studies 
conducted and screening tools that have been validated for other conditions, e.g., to 
screen for depression in epilepsy where sixteen tools were identified (Gill et al., 2017) 
or cognitive impairment in dementia where 39 screening tests were identified (Cullen et 
al., 2007). 
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With regards to the samples used, there was heterogeneity among the studies 
concerning the employment of healthy controls group, the number of participants, the 
age, the mode of presentation of the participants’ education, as also the types of epilepsy 
in which the samples belonged to. All these factors indicate a great variance in both the 
epilepsy and the comparison groups used by each study, making comparisons across 
studies hard. 
As far as the mode of administration of the test is concerned, there were both 
paper and pencil tests, and computerised tests. Validating both types in epilepsy 
populations is important for clinicians to have an idea about the applicability of the 
specific screening tests in epilepsy. Paper and pencil tests remain the most commonly 
used cognitive tests, but computerized tests are being used more and more in research 
and clinical settings. However, the grading in paper and pencil tests can be possibly 
prone to clinician’s subjectivity. On the other hand, grading in computerized tests is 
objective and consistent, but other factors can possibly intervene, such as motor 
problems of participants, which are common in neurological disorders, and indeed in 
epilepsy.  
In addition, there were substantial differences regarding the subtests that the 
screening tools are comprised of, and consequently the functions being assessed varied 
among the studies. For example, EpiTrack is focused on executive functions and 
attention, whereas NUCOG, NeuroCog FX, and CCTE additionally assess memory. 
Moreover, NUCOG also assesses visuo-constructional abilities and language. This 
raises the question of the ability of the screening tools to examine multi-dimensionally 
the cognitive status of the patients. It also raises questions of false negatives, as the 
screening tools are used to detect cognitive change in the patients; consequently, if the 
patient has a cognitive impairment in one of the domains which are not examined by the 
screening tool, false negatives will occur.  
Finally, the studies included in this review could provide more information 
regarding diagnostic accuracy. As shown in Table 4, there were studies which did not 
report one or more of the following: reliability, validity, sensitivity and specificity, 
positive/negative predictive values. 
The methodological quality assessment highlighted limitations in the literature. 
While the applicability concerns rating was defined as “low risk”, in the risk of bias 
section the quality of the studies was relatively poor, especially in the index test, 
reference standard and flow and timing sections. In these sections, all but one study had 
unclear or high risk of bias, indicating that important information regarding processes 
and methods was missing or that the results in relation to the diagnostic accuracy of the 
tools might be questioned. 
This review is the first systematic review of cognitive screening tests being used 
in epilepsy and provides clinicians with information on existing validated tools on 
epilepsy patients, including diagnostic accuracy features which may help them decide 
the most appropriate tool to use. However, a significant limitation is the heterogeneity 
among the studies, in terms of reference standards, sample sizes and characteristics 
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which did not allow for meta-analysis. In addition, the lack of reporting of diagnostic 
accuracy features, such as sensitivity and specificity, PPV and/or NPV and/or cutoff 




Relatively little research has been done in the field of cognitive screening tools in 
patients with epilepsy. The five screening tools for which validity has been examined 
would make the choice of the appropriate screening tool easier for clinicians if more 
diagnostic accuracy features had been provided. More generally, there was significant 
heterogeneity among the studies regarding sample sizes and sample demographics (e.g., 
children or adults), different clinical characteristics of patients (all epilepsy patients 
included in one group, patients separated in groups of epilepsy and non-epileptic 
seizures or include only patients with a specific sub-type such as absence epilepsy) or 
different mode of administration (paper and pencil or computerized).  
However, based on the available data, it seems that EpiTrack could be the 
preferred screening tool to start with, given that it is the only one specifically 
constructed for and validated on both adults and children with epilepsy. Moreover, it 
provides specific cutoff points and a more satisfactory level of reliability compared to 
the rest of the tests. It is, therefore, suggested that clinicians start the assessment using 
EpiTrack for screening purposes and combine it with the administration of tools 
assessing more cognitive functions if the patients’ performance and clinical image 
demand so. 
 
Future directions  
 
There is a clear clinical need for tools that accurately screen for the presence of 
cognitive impairment in people with epilepsy, but more studies are necessary, with 
more detailed reporting of results and diagnostic accuracy features, to confirm which 
tests are useful to guide clinicians’ choice of cognitive assessment instrument. Also, as 
the only screening test validated in children and adolescents is EpiTrack, the validation 
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